博九娱乐网

Vivani leverages proprietary technologies to develop and commercialize drug and device implants, including its lead asset NPM-119 (exenatide implant), which seeks to treat patients with chronic diseases with high unmet medical need. They are currently exploring strategic options for advancing Orion II, a follow-on candidate to the Orion庐 Visual Cortical Prosthesis System. This investigational…More device is intended to bring meaningful artificial vision to individuals who are profoundly blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.